KB-1401

18C3-hIgG4-S228P

45630

Home » Antibodies » 18C3-hIgG4-S228P

Background of 18C3-hIgG4-S228P

B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune checkpoint molecules. It is a protein that plays a role in the regulation of immune responses, particularly in the context of T-cell activation and proliferation. B7-H7 is expressed on human monocytes and can be induced on B cells. It is not found in mice, which makes it unique to humans. The protein is also expressed in various human cancers, and its expression is associated with poor prognostic factors in these malignancies. In summary, B7-H7 is an important immune modulatory molecule with significant expression in various human cancers. Its expression is associated with poor prognosis in certain malignancies, making it a potential biomarker and therapeutic target.

Specifications

Catalog Number	KB-1401
Antibody Name	18C3-hIgG4-S228P
Isotype	Human IgG4-S228P, kappa
Target	B7H7
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Janakiram M, Chinai JM, Zhao A, et al. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology 2015;4:e1026534. 10.1080/2162402X.2015.1026534.
Cheng H, Janakiram M, Borczuk A, et al. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. Clin Cancer Res 2017;23:825-32. 10.1158/1078-0432.CCR-15-3071.
Xiao Y, Freeman GJ. A. New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clin Cancer Res 2015;21:2201-3. 10.1158/1078-0432.CCR-14-2658.